Skip to content

H09 — Community Fermentation Reliability (Stub)

Stub status. Committed at stub-level on 2026-05-15 to register the platform's #2 load-bearing scientific bet in the falsification-card directory and force the "what would kill this thesis" framing onto cross-validation.md §Claim 5 and open-source-platform.md §"Open Questions — Reliability of Community Fermentation". Full population (assumption stack, killshot menu, pre-committed thresholds, kill switches, failure-mode coverage map) is queued as Phase 2 — see "Open Follow-Ups" at the bottom of this file.

Identified as the platform's #2 riskiest assumption in the 2026-05-13 sweep (synthesis/done/2026-05-13-riskiest-assumption-1-the-single-load-bearing-belief-in-the-current-platform.md) with Pass 3 verdict "Push back" — the push-back was on a few citation paths (corrected here), not on the substantive claim. Sister card to H08 — Gut-Lumen Sink Platform Thesis: H08 is the mechanism risk (does the gut-lumen sink produce clinically meaningful SUA reduction?); H09 is the delivery/production risk (even if the mechanism works, can it be reliably home- and community-fermented at therapeutic doses?). Both must survive for the platform's accessibility thesis to hold.

The pre-registration note on H01 (H01-ward-dual-cassette.md §Pre-registration) does not apply until this stub is upgraded to a full card.

Claim (provisional, stub-level)

Under the Community-BioLab + Home-Fermentation hybrid model (per cross-validation.md §Claim 5 — 3/10 as "Entirely Home-Based," reframed to 6/10 under the hybrid model), home and community fermenters of an engineered multi-cassette A. oryzae koji strain can produce therapeutically-active enzyme batches with batch-to-batch coefficient-of-variation < 30% across N ≥ 10 independent producers, with strain construct retention ≥ 95% at generation 5 of community-relevant propagation, and contamination rate < 5% per batch when paired with explicit "never backslop past generation N + reset from frozen master stock" guidance.

The claim has multiple sub-components that the full card will decompose:

  1. Strain stability across generations. A food-grade construct without antibiotic selection retains expression for ≥5 propagation generations when integrated chromosomally (per the existing engineered-yeast-uricase-proposal.md §2 mitigation) and propagated under "reset from master stock at generation N" discipline.
  2. Reproducibility across users. Cross-user batch CV at first-batch QC is < 30% — i.e., the variation between 10 independent home fermenters is bounded enough that "silent underdosing" (a batch producing 20% of expected titer without the user knowing) is detectable and correctable via a community-biolab first-batch QC protocol.
  3. Contamination resistance. Single-batch contamination rate is < 5% with explicit hygiene guidance; multi-generation contamination drift is detectable + reversible via master-stock reset.
  4. Drying / preservation feasibility. Heat-drying with trehalose lyoprotectant retains ≥80% of fresh-fermentate enzyme activity (or, alternatively, a community-biolab-accessible lyophilizer is part of the hybrid model's infrastructure).
  5. First-batch QC infrastructure. A user-runnable activity assay (≤$100 spectrophotometer or smartphone-camera-based colorimetric at 293 nm uric-acid absorbance) gives a go/no-go signal within 1 hour of fermentation completion, turning batch variation into a visible correctable problem rather than a silent one.
  6. Regulatory framework feasibility. A regulatory path exists for distributing engineered-organism spores to citizens within the Community-BioLab + Home-Fermentation model (or, the platform pivots to a fully-centralized-processing model and the accessibility thesis softens accordingly).

Why this is the #2 riskiest assumption

The platform's accessibility thesis ("grow it at home like sourdough") is what differentiates Open Enzyme from a conventional pharma drug. Without it, OE is just "another oral enzyme replacement therapy with a fermentation-based supply chain" — which is a defensible product but a much smaller proposition than "open-source therapeutic-enzyme platform that scales without central manufacturing." The platform thesis has two equally load-bearing risks:

  • H08 mechanism risk: even if the koji works perfectly, does the gut-lumen sink produce clinically meaningful SUA reduction in typical gout? (the −0.5 to −1.0 mg/dL band predicted by comp-019; no human RCT has validated)
  • H09 production risk (this card): even if the mechanism works, can engineered multi-cassette koji be reliably home- and community-fermented at therapeutic doses with batch-to-batch consistency? (3/10 → 6/10 in cross-validation.md Claim 5; corpus offers no direct evidence for engineered strains)

Both must survive. If H08 dies, the platform collapses to "mild adjunct" framing. If H09 dies, the platform collapses to "centrally-manufactured oral enzyme with a non-traditional supply chain" — defensible but no longer open-source-accessible. The platform's distinctive value depends on both H08 and H09 holding.

The corpus currently offers: - ✓ Strong mitigation sketches in open-source-platform.md §"Open Questions — Reliability of Community Fermentation" — chromosomal integration, first-batch QC protocol, never-backslop-past-N rule - ✓ Honest framing in cross-validation.md Claim 5 — explicitly calls "Easy as Sourdough" the most audacious and least rigorously validated claim - ✗ Zero direct empirical evidence for an engineered multi-cassette A. oryzae strain in the community-fermentation context. The Ward 1995 §1.9 dual-cassette feasibility test is the first wet-lab gate that begins to address production-side reliability, but only validates expression in a controlled lab setting — not the home-fermentation reliability question itself. - ✗ No regulatory precedent for distributing engineered-organism spores to citizens for therapeutic use.

Assumption Stack (placeholder — to be populated in Phase 2)

Anticipated load-bearing assumptions, to be confirmed and weighted in the full card:

  1. Chromosomal integration is sufficient for construct retention at community-relevant propagation generations (5 cycles, ≥95% retention). Per engineered-yeast-uricase-proposal.md §2: integrated copies far more stable than 2μ plasmids without selection; this card commits the assumption that integrated multi-cassette constructs retain ≥95% at gen 5 under the explicit master-stock-reset discipline.
  2. Industrial koji batch-CV is < 30% baseline. Commercial Japanese miso/sake koji production achieves batch-to-batch CV in this range; community fermentation will be wider but bounded by the same biology if hygiene + protocol discipline are followed.
  3. Trehalose-lyoprotected heat-drying retains ≥80% enzyme activity vs. fresh-fermentate. Documented for many proteins but not yet validated for OE's uricase + lactoferrin + DAF SCR1-4 multi-cassette strain.
  4. Smartphone-camera-based 293 nm colorimetric uric-acid-degradation assay is sufficient for go/no-go QC at the home / community-biolab level. Requires a smartphone-camera-app calibration step + uric-acid reference standard; mechanism is straightforward but UI/UX is unbuilt.
  5. A regulatory path exists (or can be developed within the Community-BioLab + Home-Fermentation framing) for distributing engineered-organism starter cultures. Likely requires FDA dialogue + community-biolab licensing precedents; no existing template.
  6. Users will follow the master-stock-reset discipline. Behavioral assumption — community fermenters returning to a frozen master at generation N rather than indefinitely backslopping. Sourdough culture suggests this is a real failure mode (sourdough starters silently drift over decades); explicit mitigation in protocol design is needed.

Killshot Menu (placeholder — to be populated in Phase 2)

Anticipated highest-priority killshots, ranked roughly by leverage:

  • Lit scan: industrial koji batch-CV baseline. Japanese miso/sake industry reports on commercial koji batch-to-batch reproducibility. Cheapest upstream prior — establishes the CV envelope community fermentation can plausibly achieve. (Opus subagent literature scan, ~1 day.)
  • Multi-user community-fermentation pilot trial. N=5–10 community-recruited home fermenters, single distributed engineered strain, central QC at a community biolab. Cost: ~$5K–10K (strain shipment + QC reagents); 4–8 weeks. Directly tests cross-user batch CV.
  • Passaging-based strain stability test. Serial passaging of the engineered multi-cassette koji for 50 generations under "no selection" conditions; qPCR or activity assay at each generation to measure construct retention. Cost: ~$2K (reagents + community-biolab time); 6–8 weeks. Directly tests assumption 1.
  • Drying activity-retention comparison. Lyophilized vs. oven-dried vs. trehalose-lyoprotected oven-dried, measured uricase + lactoferrin + DAF SCR1-4 activity retention. Cost: ~$1K; 2–3 weeks. Directly tests assumption 3.
  • Deliberate contamination spike test. Introduce wild A. oryzae + wild S. cerevisiae at known ratio to the engineered strain; monitor co-fermentation dynamics over 5 generations with + without master-stock-reset discipline. Cost: ~$1K; 4 weeks. Directly tests contamination-drift assumption.
  • Smartphone-camera colorimetric assay validation. Build the calibration protocol against a spectrophotometer reference; test reproducibility across smartphone models + lighting conditions; cost: ~$500 + 1 week development. Validates assumption 4.
  • Regulatory framework scoping pass. Engagement with FDA + community-biolab regulatory consultants (e.g., Genspace, BioCurious networks) to scope the engineered-spore distribution path. Likely identifies blockers + creative-path-forward options. Cost: ~$2K–5K consultant fees; 4–6 weeks. Validates assumption 5.

Pre-Committed Thresholds (placeholder — to be populated in Phase 2)

To be defined when the killshot menu is populated. Provisional anchors (to be confirmed in full card):

  • Alive: any future multi-user community-fermentation trial showing cross-user CV < 30% on enzyme activity AND strain retention ≥ 95% at gen 5 AND contamination rate < 5% per batch.
  • Killed: any of the above thresholds materially missed in a properly-powered pilot (e.g., CV > 50% across N ≥ 10 users; strain retention < 80% at gen 5; contamination > 15% per batch under standard hygiene protocol).
  • Pending: anything in between, including single-batch successes that don't generalize across users.

Failure Modes Probed (placeholder — to be populated in Phase 2)

Anticipated relevant failure modes from linter-design.md §5:

  • environmental-variation — humidity, temperature, substrate quality variation across home fermenters; the "100 kitchens" problem
  • selection-loss — construct loss without antibiotic selection pressure; the central tension behind the master-stock-reset discipline
  • contamination-drift — multi-generation co-fermentation with wild-type contaminants
  • assay-gap — no home-runnable QC for engineered-strain identity or activity (smartphone colorimetric is unbuilt)
  • regulatory-precedent gap — no FDA framework for engineered-organism distribution to citizens
  • behavioral-adherence gap — assumption that community fermenters will follow protocol discipline (master-stock reset, hygiene practices)
  • scale-variation — therapeutic-relevant batch sizes (g of dried product per dose × N doses per month per user) vs. hobby-scale sourdough batches

Status

Stub. No killshot executed. No assumption stack pre-registered. Full hypothesis card is queued as Phase 2 — see "Open Follow-Ups" below.

Survival count: 0.

Survival score: 0.0 (undefined until full card and first survived killshot).

Open Follow-Ups (Phase 2)

ID Item Type Status
P2-1 Lit scan: industrial koji batch-CV baseline (Japanese miso/sake reproducibility data) Opus subagent literature scan Queued
P2-2 Multi-user community-fermentation pilot trial design (N=5–10, single strain, central QC) Foreground subagent + protocol authoring Queued
P2-3 Passaging-based strain stability protocol (50 generations, qPCR/activity readout) Inline protocol authoring + validation-experiments.md §X.Y entry Queued
P2-4 Drying activity-retention comparison protocol (lyophilization vs. oven-dry vs. trehalose-lyoprotected) Inline validation-experiments.md §X.Y entry Queued
P2-5 Contamination-spike test protocol (wild-strain spike, 5-generation tracking) Inline validation-experiments.md §X.Y entry Queued
P2-6 Smartphone-camera colorimetric uric-acid assay validation (calibration + cross-device reproducibility) Subagent design + community-biolab test Queued
P2-7 Populate full assumption stack, weights, and confidence tiers per H01 template Inline upgrade Queued
P2-8 Populate full killshot menu with score-ranking per linter-design.md §4–5 Inline upgrade Queued
P2-9 Populate pre-committed thresholds + kill switches Inline upgrade (requires P2-1 + P2-2 results to anchor magnitudes) Queued
P2-10 Failure-mode coverage map (lint cross-check against linter-design.md §5) Inline upgrade Queued
P2-11 Regulatory framework scoping pass (engineered-spore distribution path) External consultant engagement Queued (deferred — user-action-required)

Tracked across the 6 follow-up surfaces per the walk-synthesis skill §5: 1. This page's "Open Follow-Ups" section (above) 2. open-questions.md §Platform/Strategic — to be added in same commit 3. computational-experiments.md — no comp-NNN assigned yet; production-reliability is primarily a wet-lab + behavioral question 4. This H09 falsification card stub (current) 5. index.md — extends the existing H08 riskiest-assumption anchor to surface BOTH H08 (mechanism) and H09 (production) 6. synthesis/done/2026-05-13-riskiest-assumption-1-the-single-load-bearing-belief-in-the-current-platform.md — closure annotation

Cross-References